Our goal is to inform policymakers of the unique challenges—and promises—we face in taking these rare disease drugs from research through development, approval and manufacturing and to advocate for government policies that enable positive changes to be realized for the rare disease community. We are invested – On average, 52% of our annual expenditures go to research and development. We represent life science companies committed to discovering, developing, and delivering rare disease treatments for the patients we serve.
Washington, United States
Founded in 2021
1-10 Employees
Startup
Working industry
Pharmaceuticals
Type of company
-
Ownership structure
Partnership
Locations
1 Headquarter
Number of products
6 Products
Number of services
8 Services
Specialised areas
Pharmaceuticals
The Rare Disease Company Coalition offers a wide range of products and services
Service
The Rare Disease Company Coalition Applauds Introduction of Cures 2.0 and Encourages Congress to Account for the Unique Circumstances in Rare Disease Treatment Development - Rare Coalition
Go to product >
Service
RARECast Podcast: Examining the Legislative Landscape for Rare Disease Drug Development - Rare Coalition
Go to product >
Product
Policy Must Keep Pace with Technology if we are to Reap the Benefits of AI Drug Discovery for Rare Diseases - Rare Coalition
Go to product >
Service
The Orphan Drug Tax Credit is a Proven Catalyst for Investment and Treatment Development - Rare Coalition
Go to product >
Service
RDCC Offers Endorsement of the Bipartisan BENEFIT Act in Support of Patient Engagement in Drug Development - Rare Coalition
Go to product >
Product
Celebrating 40 Years of the Orphan Drug Act: Renewing a Commitment to Advancing Innovation for Rare Disease Patients - Rare Coalition
Go to product >
Product
Existing Value Frameworks to Negotiate Pricing for Rare Disease Drugs Disproportionately Impacts People Suffering from Rare Diseases - Rare Coalition
Go to product >
Product
RDCC Joins in Call for Repeal of R&D Tax Policy that Hurts Rare Disease Innovation - Rare Coalition
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Get insights into the use cases of The Rare Disease Company Coalition
Use case
The Rare Disease Company Coalition Submits Comments on Oregon’s Application for a Section 1115 Demonstration Waiver - Rare Coalition
Earlier this month, our Coalition expressed concern to the Oregon Health Authority (OHA) on the proposed renewal and amendment of its Section 1115 waiver. We are a Coalition of biotech companies dedicated to the research, development and delivery of innovative treatments for rare diseases with over 225 rare disease development programs in process, we are […]
Use case
The Case for Rare Diseases as a Public Health Priority - Rare Coalition
Rare diseases represent a major societal issue with enormous costs and without a clear, concentrated, whole-of-society effort to address the burden on patients, families and caregivers.
The Rare Disease Company Coalition operates in 1 country around the world
Get an overview of the locations of The Rare Disease Company Coalition
Location
Country
State
City
Headquarter
United States
District of Columbia
Washington
Some frequent questions that have been asked about The Rare Disease Company Coalition
Where is The Rare Disease Company Coalition located?
The company headquarter of The Rare Disease Company Coalition is located in Washington, District of Columbia, United States. It's worth noting, that the company may have more locations
How many employees does The Rare Disease Company Coalition approximately have?
As of the latest available information The Rare Disease Company Coalition has around 1-10 employees worldwide.
When was The Rare Disease Company Coalition founded?
The Rare Disease Company Coalition was founded in 2021
In which industries does The Rare Disease Company Coalition mainly work?
The company The Rare Disease Company Coalition has it's main focus in the industries of Pharmaceuticals
What is the current company status of The Rare Disease Company Coalition?
Based on the founding year and the amount of employees the company The Rare Disease Company Coalition seems to be a Startup at the current state. Note that over time that status can change
Check out some interesting alternative companies to The Rare Disease Company Coalition
Sentynl Therapeutics, Inc.
Solana Beach, United States
11-50 Employees
2014
Our goal is to provide novel biopharmaceutical medicines that extend, improve, or enhance the lives of people with rare diseases. We are driven to make an impact for patients and their caregivers—from early detection to therapeutic intervention. We are committed to providing differentiated, high-quality solutions that address unmet medical needs for those who suffer from rare diseases.
HRA PHARMA RARE DISEASES
Châtillon, France
11-50 Employees
1996
We are passionate about improving the lives of people affected by these conditions. We are confident that through innovative ideas, robust science and a passionate and highly focused team, we can elevate the needs of patients living with a rare disease and help to reduce the differences in the quality of their care that exist across the globe. We are passionate about improving the lives of patients with rare and ultra-rare diseases. HRA Pharma Rare Diseases is dedicated to bringing the best care and services to people living with rare diseases and is committed to supporting healthcare professionals all over the world. By partnering with the community, we are committed to tackling current challenges, reducing the time to accurate diagnosis, enabling global access to treatment and offering effective options for the long-term management of rare diseases.
Cure Rare Disease
Boston, United States
1-10 Employees
2017
Through collaborations with world-renowned academics and clinicians, we are moving science forward to develop life-saving gene therapies for rare and ultra-rare disease patients overlooked and underserved by traditional drug development efforts. Our collaborative framework reimagines the drug development process to provide an accelerated pathway for the development of life-saving therapeutics that previously did not exist for people with rare and ultra-rare neuromuscular diseases. Moreover, our model offers industry collaborators a mechanism to expand their drug development pipeline. As the scope of our research and development grows, so does our need to expand our network of collaborators to advance therapeutics for rare and ultra-rare neuromuscular diseases, speed drug development for orphan diseases, and expand access to treatments to broader populations.
Recordati Rare Diseases Benelux
Jette, Belgium
11-50 Employees
-
We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors and the people across the globe who we serve. We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries. At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment.
Rare Insight Consulting
Parma, Italy
1-10 Employees
2016
We are aware that the ultimate goal of our work is to improve the lives of patients suffering from rare diseases. RareInsight consulting is one of the 5 members of BlueDil International. To be the point of reference for healthcare companies that intend to operate in the Italian orphan drugs market, thus helping to improve the quality of life of rare disease patients. We offer strategic support and operational solutions that are personalized, flexible and value-generating to healthcare companies offering effective therapies to people suffering from rare and severe diseases. We believe that it is essential to know the history of our customers, and understand how they create value so as to be able to support them. We believe that active listening and open communication is essential. We believe it is important to understand in which direction our society will progress and contribute to its sustainable improvement. We believe that rigorous application of scientific methods is essential for interpreting data which helps communicating facts about diseases and their management.
Twist Health
Winchester, United Kingdom
1-10 Employees
2018
At our core, we're dedicated to understanding the environmental healthcare issues affecting our patients and healthcare providers (HCPs). Its not easy in rare disease to see where to invest budgets to provide return.
